We are live on ! Find out more
IPHA

Innate Pharma
IPHA

18 hedge funds and large institutions have $5.82M invested in Innate Pharma in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,866% more capital invested

Capital invested by funds: $296K → $5.82M (+$5.52M)

260% more funds holding

Funds holding: 5 → 18 (+13)

1.08% more ownership

Funds ownership: 0.11% → 1.19% (+1.1%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
18
Holders Change
+13
Holders Change %
+260%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$808K
2
Bank of America
Bank of America
North Carolina
+$750K
3
AAA
Affinity Asset Advisors
New York
+$539K
4
VF
Virtu Financial
New York
+$472K
5
Optiver Holding
Optiver Holding
Netherlands
+$450K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$84.7K
2
Morgan Stanley
Morgan Stanley
New York
-$81.4K
3
SPIA
Steward Partners Investment Advisory
New York
-$646
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
1
Balyasny Asset Management
Illinois
$1.16M +$808K +187,484 New
Bank of America
2
Bank of America
North Carolina
$1.07M +$750K +174,100 New
AAA
3
Affinity Asset Advisors
New York
$771K +$539K +125,000 New
VF
4
Virtu Financial
New York
$676K +$472K +109,572 New
Optiver Holding
5
Optiver Holding
Netherlands
$673K +$450K +104,546 +2,327%
PVI
6
Pura Vida Investments
New York
$509K +$355K +82,509 New
Millennium Management
7
Millennium Management
New York
$167K -$84.7K -19,649 -42%
Jane Street
8
Jane Street
New York
$151K +$105K +24,430 New
CSS
9
Cubist Systematic Strategies
Connecticut
$124K +$86.7K +20,132 New
Two Sigma Investments
10
Two Sigma Investments
New York
$116K +$81.1K +18,829 New
LPL Financial
11
LPL Financial
California
$114K +$79.3K +18,400 New
Morgan Stanley
12
Morgan Stanley
New York
$109K -$81.4K -18,901 -52%
TSS
13
Two Sigma Securities
New York
$106K +$73.8K +17,119 New
TRCT
14
Tower Research Capital (TRC)
New York
$44K +$31.1K +7,210 New
Osaic Holdings
15
Osaic Holdings
Arizona
$12K +$4.31K +1,000 +100%
PHK
16
Point72 Hong Kong
Hong Kong
$6K +$4.06K +943 New
VRM
17
Vectors Research Management
New York
$6K +$4.31K +1,000 New
SPIA
18
Steward Partners Investment Advisory
New York
$3K -$646 -150 -23%

IPHA Hedge Fund Activity: Q3 2021 in Review

18 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2021, worth a combined $5.82M — up 1,866% from $296K a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new IPHA positions and 0 closed out — a net gain of 13 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $808K. The largest seller was Millennium Management, cutting an estimated $84.7K.

  • 18 institutional investors held Innate Pharma (IPHA) as of Q3 2021, up from 5 in Q2 2021.
  • Funds reported $5.82M of Innate Pharma stock for Q3 2021, up 1,866% quarter-over-quarter.
  • 13 funds opened new Innate Pharma positions in Q3 2021 and 0 closed out, a net change of +13 holders.
  • The largest Innate Pharma buyer in Q3 2021 was Balyasny Asset Management, an estimated $808K added.
  • The largest Innate Pharma seller in Q3 2021 was Millennium Management, an estimated $84.7K sold.

Based on aggregated 13F filings for Q3 2021.